Abcellera Biologics Inc
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for… Read more
Abcellera Biologics Inc (ABCL) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.030x
Based on the latest financial reports, Abcellera Biologics Inc (ABCL) has a cash flow conversion efficiency ratio of -0.030x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-34.74 Million) by net assets ($1.14 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Abcellera Biologics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Abcellera Biologics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Abcellera Biologics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Abcellera Biologics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Whitestone REIT
NYSE:WSR
|
0.079x |
|
Hanwha Corp. Pfd. Series 1
KO:000885
|
0.114x |
|
Patria Investments Ltd
NASDAQ:PAX
|
0.103x |
|
Standard Motor Products Inc
NYSE:SMP
|
0.132x |
|
Taiflex Scientific Co Ltd
TW:8039
|
0.090x |
|
Ratos AB (publ)
PINK:RTOBF
|
0.063x |
|
Hanmi Financial Corporation
NASDAQ:HAFC
|
0.184x |
|
Medartis Holding AG
PINK:MDRSF
|
0.033x |
Annual Cash Flow Conversion Efficiency for Abcellera Biologics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Abcellera Biologics Inc from 2018 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.14 Billion | $-131.29 Million | -0.115x | -11.91% |
| 2024-12-31 | $1.06 Billion | $-108.56 Million | -0.103x | -169.95% |
| 2023-12-31 | $1.15 Billion | $-43.88 Million | -0.038x | -116.93% |
| 2022-12-31 | $1.23 Billion | $277.36 Million | 0.225x | -5.68% |
| 2021-12-31 | $1.03 Billion | $244.58 Million | 0.238x | +772.78% |
| 2020-12-31 | $830.51 Million | $22.69 Million | 0.027x | -89.60% |
| 2019-12-31 | $10.25 Million | $2.69 Million | 0.263x | -14.43% |
| 2018-12-31 | $11.61 Million | $3.56 Million | 0.307x | -- |